Physician profile
Brian Bello
NPI 1902234651
$7,566.51
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $495 · 2020: $1,591 · 2021: $2,953 · 2022: $2,183 · 2023: $124 · 2024: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $344.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,069.39 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $885.79 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $790.17 | 2019-2023 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $744.39 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $696.47 | 2020-2022 | |
| Vanda Pharmaceuticals INC. | $590.17 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $425.13 | 2021-2024 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $410.12 | 2019-2022 | |
| Lundbeck LLC | $333.54 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $303.73 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $242.18 | 2020-2022 | |
| Allergan, INC. | $204.26 | 2020 | |
| Adlon Therapeutics L.P. | $183.27 | 2020-2021 | |
| Eisai INC. | $138.51 | 2020-2021 | |
| Abbvie INC. | $106.58 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $64.95 | 2022 | |
| Neos Therapeutics, Lp | $60.23 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $56.87 | 2020-2022 | |
| Almatica Pharma LLC | $48.62 | 2021-2022 | |
| Neuronetics, INC. | $46.70 | 2022 | |
| Indivior INC. | $40.43 | 2019-2021 | |
| Harmony Biosciences LLC | $38.71 | 2023 | Wakix |
| Bausch Health US, LLC | $26.17 | 2020 | |
| Sun Pharmaceutical Industries INC. | $21.85 | 2021 | |
| Merck Sharp & Dohme LLC | $20.76 | 2022 | |
| Noven Therapeutics, LLC | $17.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Bello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.